FDA new drug approvals in Q1 2021

被引：5
|
作者：
Urquhart, Lisa [1 ]
机构：
[1] Evaluate Vantage, London, England
来源：
NATURE REVIEWS DRUG DISCOVERY | 2021年 / 20卷 / 05期
关键词：
D O I：
10.1038/d41573-021-00067-x
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
引用
收藏
页码：334 / 334
页数：1
相关论文
共 50 条
  • [31] 2021 FDA approvals
    Asher Mullard
    Nature Reviews Drug Discovery, 2022, 21 : 83 - 88
  • [32] FDA Guidance and New Drug Approvals
    Walker, Scot
    HOSPITAL PHARMACY, 2018, 53 (06) : 360 - 362
  • [33] 2021 in review: FDA approvals of new medicines
    Kinch, Michael S.
    Kraft, Zachary
    Schwartz, Tyler
    DRUG DISCOVERY TODAY, 2022, 27 (08) : 2057 - 2064
  • [34] MARKET WATCH FDA new drug approvals in Q2 2019
    Urquhart, Lisa
    NATURE REVIEWS DRUG DISCOVERY, 2019, 18 (08) : 575 - 575
  • [35] MARKET WATCH FDA new drug approvals in Q2 2022
    Urquhart, Lisa
    NATURE REVIEWS DRUG DISCOVERY, 2022, 21 (08) : 550 - 550
  • [36] Recent and anticipated novel drug approvals (Q2 2024 through Q1 2025)
    Rim, Matthew H.
    Karas, Brittany L.
    Barada, Farah
    Dean, Collin
    Levitsky, Andrew M.
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2024, 81 (16) : 733 - 738
  • [37] Approvals in 2021: dangling Accelerated Approvals, drug dosing, new approvals and beyond
    Lemery, Steven
    Pazdur, Richard
    NATURE REVIEWS CLINICAL ONCOLOGY, 2022, 19 (04) : 217 - 218
  • [38] Approvals in 2021: dangling Accelerated Approvals, drug dosing, new approvals and beyond
    Steven Lemery
    Richard Pazdur
    Nature Reviews Clinical Oncology, 2022, 19 : 217 - 218
  • [39] FDA marks record year for new drug approvals
    Challener, Cynthia A.
    Pharmaceutical Technology, 2019, 43 (01) : 30 - 33
  • [40] 2015 FDA drug approvals
    Asher Mullard
    Nature Reviews Drug Discovery, 2016, 15 : 73 - 76
12345